Main cancers (summary list)
Five-year relative survival by sex (diagnosis period 2003-2007)
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
all except NMSC |
all 15-99 |
59.5% |
58.5% |
60.5% |
|||
|
(ICD10 C00-C97 ex C44) |
(unstandardized) |
(58.9-60%) |
(57.7-59.2%) |
(59.7-61.2%) |
|||
|
all except NMSC |
all 15-99 |
56.4% |
56.6% |
55.5% |
|||
|
(ICD10 C00-C97 ex C44) |
(age-standardized)# |
(55.3-57.4%) |
(55.0-58.1%) |
(54.0-56.9%) |
|||
|
head & neck |
all 15-99 |
50.3% |
43.6% |
63.2% |
|||
|
(ICD10 C01-C06,C09-C13) |
(unstandardized) |
(46.1-54.4%) |
(38.4-48.7%) |
(57.0-70.4%) |
|||
|
head & neck |
all 15-99 |
44.3% |
37.0% |
55.1% |
|||
|
(ICD10 C01-C06,C09-C13) |
(age-standardized)# |
(35.6-52.9%) |
|||||
|
oesophagus |
all 15-99 |
15.8% |
15.8% |
16.0% |
|||
|
(ICD10 C15) |
(unstandardized) |
(13.3-18.6%) |
(12.6-19.3%) |
(12.0-20.4%) |
|||
|
oesophagus |
all 15-99 |
16.2% |
15.5% |
17.9% |
|||
|
(ICD10 C15) |
(age-standardized)# |
(10.9-22.4%) |
|||||
|
stomach |
all 15-99 |
23.9% |
24.6% |
22.8% |
|||
|
(ICD10 C16) |
(unstandardized) |
(21.4-26.4%) |
(21.4-27.8%) |
(19.0-26.9%) |
|||
|
stomach |
all 15-99 |
23.4% |
23.3% |
23.7% |
|||
|
(ICD10 C16) |
(age-standardized)# |
(18.4-28.8%) |
|||||
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
colorectal |
all 15-99 |
57.6% |
56.7% |
58.6% |
|||
|
(ICD10 C18-C21) |
(unstandardized) |
(56.0-59.1%) |
(54.5-58.8%) |
(56.3-60.8%) |
|||
|
colorectal |
all 15-99 |
57.0% |
56.2% |
58.0% |
|||
|
(ICD10 C18-C21) |
(age-standardized)# |
(53.7-60.2%) |
|||||
|
colon |
all 15-99 |
57.7% |
57.6% |
57.8% |
|||
|
(ICD10 C18) |
(unstandardized) |
(55.7-59.6%) |
(54.7-60.3%) |
(55.0-60.5%) |
|||
|
colon |
all 15-99 |
57.6% |
57.5% |
57.4% |
|||
|
(ICD10 C18) |
(age-standardized)# |
(53.4-71.7%) |
|||||
|
rectum/anus |
all 15-99 |
57.4% |
55.6% |
60.2% |
|||
|
(ICD10 C19-C21) |
(unstandardized) |
(54.8-59.8%) |
(52.3-58.8%) |
(56.2-63.9%) |
|||
|
rectum/anus |
all 15-99 |
55.8% |
54.4% |
58.4% |
|||
|
(ICD10 C19-C21) |
(age-standardized)# |
(50.5-61.0%) |
|||||
|
pancreas |
all 15-99 |
6.2% |
3.8% |
8.6% |
|||
|
(ICD10 C25) |
(unstandardized) |
(4.6-8.0%) |
(2.1-6.1%) |
(6.2-11.5%) |
|||
|
pancreas |
all 15-99 |
7.3% |
- |
10.3% |
|||
|
(ICD10 C25) |
(age-standardized)# |
(4.0-11.8%) |
|||||
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
liver |
all 15-99 |
12.9% |
14.7% |
9.8% |
|||
|
(ICD10 C22) |
(unstandardized) |
(9.4-17.0%) |
(10.1-20.1%) |
(5.1-16.4%) |
|||
|
liver |
all 15-99 |
13.3% |
13.7% |
- |
|||
|
(ICD10 C22) |
(age-standardized)# |
(6.6-22.6%) |
|||||
|
larynx |
all 15-99 |
57.9% |
58.2% |
56.1% |
|||
|
(ICD10 C32) |
(unstandardized) |
(51.8-63.7%) |
(51.5-64.4%) |
(40.0-70.5%) |
|||
|
larynx |
all 15-99 |
56.2% |
58.1% |
46.4% |
|||
|
(ICD10 C32) |
(age-standardized)# |
(42.7-68.1%) |
|||||
|
lung & trachea |
all 15-99 |
11.7% |
9.7% |
14.6% |
|||
|
(ICD10 C33-C34) |
(unstandardized) |
(10.7-12.7%) |
(8.58-10.9%) |
(12.9-16.2%) |
|||
|
lung & trachea |
all 15-99 |
12.7% |
10.7% |
15.5% |
|||
|
(ICD10 C33-C34) |
(age-standardized)# |
(10.5-15.2%) |
|||||
|
bone & cartilage |
all 15-99 |
64.4% |
61.4% |
64.7% |
|||
|
(ICD10 C40-C41) |
(unstandardized) |
(52.9-74.2%) |
(46.5-73.8%) |
(46.9-79.0%) |
|||
|
bone & cartilage |
all 20-99 |
67.0% |
57.9% |
65.8% |
|||
|
(ICD10 C40-C41) |
(age-standardized)# |
||||||
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
melanoma of skin |
all 15-99 |
86.6% |
82.2% |
89.6% |
|||
|
(ICD10 C43) |
(unstandardized) |
(84.1-88.8%) |
(78.0-86%) |
(86.5-92.2%) |
|||
|
melanoma of skin |
all 15-99 |
86.0% |
81.0% |
88.8% |
|||
|
(ICD10 C43) |
(age-standardized)# |
(80.5-90.5%) |
|||||
|
soft tissue |
all 15-99 |
63.3% |
62.5% |
64.3% |
|||
|
(ICD10 C47 & C49) |
(unstandardized) |
(56.1-70.0%) |
(52.5-71.6%) |
(53.7-73.8%) |
|||
|
soft tissue |
all 15-99 |
63.3% |
59.8% |
67.0% |
|||
|
(ICD10 C47 & C49) |
(age-standardized)# |
(48.5-75.6%) |
|||||
|
breast |
all 15-99 |
73.9% |
85.0% |
||||
|
(ICD10 C50) |
(unstandardized) |
(48.9-93.0%) |
(83.8-86.1%) |
||||
|
breast |
all 15-99 |
- |
81.8% |
||||
|
(ICD10 C50) |
(age-standardized)# |
(78.6-84.7%) |
|||||
|
cervix uteri |
all 15-99 |
- |
- |
66.2% |
|||
|
(ICD10 C53) |
(unstandardized) |
(62.2-69.8%) |
|||||
|
cervix uteri |
all 15-99 |
- |
- |
55.8% |
|||
|
(ICD10 C53) |
(age-standardized)# |
(45.6-66.2%) |
|||||
|
corpus uteri |
all 15-99 |
- |
- |
77.3% |
|||
|
(ICD10 C54) |
(unstandardized) |
(73.6-80.6%) |
|||||
|
corpus uteri |
all 15-99 |
- |
- |
72.5% |
|||
|
(ICD10 C54) |
(age-standardized)# |
(64.0-79.9%) |
|||||
|
ovary & uterine adnexa |
all 15-99 |
- |
- |
38.9% |
|||
|
(ICD10 C56 & C57.0-57.7)~ |
(unstandardized) |
(35.6-42.1%) |
|||||
|
ovary & uterine adnexa |
all 15-99 |
- |
- |
31.3% |
|||
|
(ICD10 C56 & C57.0-57.7) |
(age-standardized)# |
(25.4-37.4%) |
|||||
|
prostate |
all 15-99 |
- |
92.8% |
- |
|||
|
(ICD10 C61) |
(unstandardized) |
(91.5-94.0%) |
|||||
|
prostate |
all 15-99 |
- |
89.9% |
- |
|||
|
(ICD10 C61) |
(age-standardized)# |
(86.7-92.8%) |
|||||
|
testis |
all 15-99 |
- |
97.0% |
- |
|||
|
(ICD10 C62) |
(unstandardized) |
(95.0-98.3%) |
|||||
|
testis |
15-64 |
- |
97.0% |
- |
|||
|
(ICD10 C62) |
(age-standardized)# |
||||||
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
kidney & related |
all 15-99 |
57.5% |
55.8% |
60.1% |
|||
|
(ICD10 C64-66 & C68) |
(unstandardized) |
(54.0-60.8%) |
(51.2-60.3%) |
(54.8-65.1%) |
|||
|
kidney & related |
all 15-99 |
53.7% |
50.5% |
57.9% |
|||
|
(ICD10 C64-66 & C68) |
(age-standardized)# |
(46.8-60.4%) |
|||||
|
bladder |
all 15-99 |
69.4% |
70.7% |
66.2% |
|||
|
(ICD10 C67) |
(unstandardized) |
(65.9-72.7%) |
(66.3-74.8%) |
(60.5-71.5%) |
|||
|
bladder |
all 15-99 |
69.2% |
70.3% |
65.9% |
|||
|
(ICD10 C67) |
(age-standardized)# |
(61.9-75.5%) |
|||||
|
brain |
all 15-99 |
19.1% |
17.4% |
20.8% |
|||
|
(ICD10 C71) |
(unstandardized) |
(16.3-22%) |
(13.8-21.3%) |
(16.8-25.0%) |
|||
|
brain |
all 15-99 |
21.4% |
18.8% |
25.5% |
|||
|
(ICD10 C71) |
(age-standardized)# |
(16.3-27.4%) |
|||||
|
thyroid |
all 15-99 |
84.7% |
76.5% |
87.2% |
|||
|
(ICD10 C73) |
(unstandardized) |
(78.7-89.4%) |
(62.8-87.0%) |
(80.7-92.2%) |
|||
|
thyroid |
all 15-99 |
76.1% |
71.5% |
77.2% |
|||
|
(ICD10 C73) |
(age-standardized)# |
(60.4-87.0%) |
|||||
|
Cancer type |
Five-year relative survival (with 95% confidence interval) (2003-2007 diagnosis period) |
||||||
|
(EUROCARE definitions) |
Age at diagnosis |
Both sexes |
Men |
Women |
|||
|
Hodgkin lymphoma |
all 15-99 |
87.5% |
85.8% |
88.6% |
|||
|
(ICD10 C81) |
(unstandardized) |
(83.2-91.0%) |
(79.8-90.5%) |
(81.9-93.4%) |
|||
|
Hodgkin lymphoma |
all 15-99 |
84.1% |
81.5% |
87.0% |
|||
|
(ICD10 C81) |
(age-standardized)# |
||||||
|
Non-Hodgkin lymphoma |
all 15-99 |
67.7% |
65.6% |
68.9% |
|||
|
(ICD10 C82-C85 & C96) |
(unstandardized) |
(64.9-70.3%) |
(61.5-69.4%) |
(65.2-72.4%) |
|||
|
Non-Hodgkin lymphoma |
all 15-99 |
61.1% |
57.0% |
64.9% |
|||
|
(ICD10 C82-C85 & C96) |
(age-standardized)# |
(55.3-66.7%) |
|||||
|
multiple myeloma |
all 15-99 |
41.9% |
40.2% |
43.8% |
|||
|
(ICD10 C90) |
(unstandardized) |
(37.1-46.7%) |
(33.8-46.7%) |
(36.6-50.9%) |
|||
|
multiple myeloma |
all 15-99 |
42.7% |
39.5% |
45.9% |
|||
|
(ICD10 C90) |
(age-standardized)# |
(32.8-51.8%) |
|||||
|
leukaemia |
all 15-99 |
59.4% |
60.5% |
57.8% |
|||
|
(ICD10 C91-C95) |
(unstandardized) |
(56.0-62.7%) |
(56.0-64.7%) |
(52.3-63.0%) |
|||
|
leukaemia |
all 15-99 |
56.2% |
56.5% |
55.9% |
|||
|
(ICD10 C91-C95) |
(age-standardized)# |
(49.2-62.8%) |
|||||
|
Footnotes: |
|
|
|
|
Exclusions (as in EUROCARE except for bladder): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-diagnosed malignancies); |
|
|
in situ carcinomas and tumours of uncertain behaviour (both INCLUDED for bladder by EUROCARE but not here). |
|
|
|
|
*All-cancer figures exclude non-melanoma skin cancers (NMSC), which are rarely fatal |
|
|
|
|
~ Definition of cancer of the ovary and uterine adnexa used here & in EUROCARE-4 = ICD10 codes C56 and C57.0-C57.7 |
|
|
with the exception of 'borderline' morphologies (not considered malignant in ICDO3). |
|
|
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|